NADIDE (NAD+) is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. NADIDE was marketed under the brand name Enada. Although Enada (NADH) is marketed as a nutritional supplement, Birkmayer Pharmaceuticals has launched two clinical trials to prove scientifically that Enada is effective. Before these studies could get started they had to also prove to the Food and Drug Administration (FDA) that the stable oral form of Enada (NADH) is a safe substance. Since the mid-‘80s more than 3,000 parkinsonian patients have received NADH, either as intravenous infusion or in the form of oral tablets. Enada (NADH) is the world‘s first and only stabilized, absorbable, patented, tablet-form NADH dietary supplement. It is now available to everyone whose lifestyle demands increased energy, vitality and mental clarity. In other words, it is beneficial not only for patients suffering from chronic fatigue syndrome, Alzheimer‘s disease, depression or Parkinson‘s disease, but for any normal, healthy individual whose lifestyle demands more energy. NADIDE (NADH) may be considered as a therapeutic adjunct for cancer patients to protect them against the general toxic effects of substances such as doxorubicin or cisplatin by stimulating the DNA repair system and by promoting normal cellular biosynthetic responses after chemotherapy. NADH seems to exhibit a chemo preventive effect.

NADIDE (NAD+) is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. NADIDE was marketed under the brand name Enada. Although Enada (NADH) is marketed as a nutritional supplement, Birkmayer Pharmaceuticals has launched two clinical trials to prove scientifically that Enada is effective. Before these studies could get started they had to also prove to the Food and Drug Administration (FDA) that the stable oral form of Enada (NADH) is a safe substance. Since the mid-‘80s more than 3,000 parkinsonian patients have received NADH, either as intravenous infusion or in the form of oral tablets. Enada (NADH) is the world‘s first and only stabilized, absorbable, patented, tablet-form NADH dietary supplement. It is now available to everyone whose lifestyle demands increased energy, vitality and mental clarity. In other words, it is beneficial not only for patients suffering from chronic fatigue syndrome, Alzheimer‘s disease, depression or Parkinson‘s disease, but for any normal, healthy individual whose lifestyle demands more energy. NADIDE (NADH) may be considered as a therapeutic adjunct for cancer patients to protect them against the general toxic effects of substances such as doxorubicin or cisplatin by stimulating the DNA repair system and by promoting normal cellular biosynthetic responses after chemotherapy. NADH seems to exhibit a chemo preventive effect.

NADIDE (NAD+) is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. NADIDE was marketed under the brand name Enada. Although Enada (NADH) is marketed as a nutritional supplement, Birkmayer Pharmaceuticals has launched two clinical trials to prove scientifically that Enada is effective. Before these studies could get started they had to also prove to the Food and Drug Administration (FDA) that the stable oral form of Enada (NADH) is a safe substance. Since the mid-‘80s more than 3,000 parkinsonian patients have received NADH, either as intravenous infusion or in the form of oral tablets. Enada (NADH) is the world‘s first and only stabilized, absorbable, patented, tablet-form NADH dietary supplement. It is now available to everyone whose lifestyle demands increased energy, vitality and mental clarity. In other words, it is beneficial not only for patients suffering from chronic fatigue syndrome, Alzheimer‘s disease, depression or Parkinson‘s disease, but for any normal, healthy individual whose lifestyle demands more energy. NADIDE (NADH) may be considered as a therapeutic adjunct for cancer patients to protect them against the general toxic effects of substances such as doxorubicin or cisplatin by stimulating the DNA repair system and by promoting normal cellular biosynthetic responses after chemotherapy. NADH seems to exhibit a chemo preventive effect.

NADIDE (NAD+) is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. NADIDE was marketed under the brand name Enada. Although Enada (NADH) is marketed as a nutritional supplement, Birkmayer Pharmaceuticals has launched two clinical trials to prove scientifically that Enada is effective. Before these studies could get started they had to also prove to the Food and Drug Administration (FDA) that the stable oral form of Enada (NADH) is a safe substance. Since the mid-‘80s more than 3,000 parkinsonian patients have received NADH, either as intravenous infusion or in the form of oral tablets. Enada (NADH) is the world‘s first and only stabilized, absorbable, patented, tablet-form NADH dietary supplement. It is now available to everyone whose lifestyle demands increased energy, vitality and mental clarity. In other words, it is beneficial not only for patients suffering from chronic fatigue syndrome, Alzheimer‘s disease, depression or Parkinson‘s disease, but for any normal, healthy individual whose lifestyle demands more energy. NADIDE (NADH) may be considered as a therapeutic adjunct for cancer patients to protect them against the general toxic effects of substances such as doxorubicin or cisplatin by stimulating the DNA repair system and by promoting normal cellular biosynthetic responses after chemotherapy. NADH seems to exhibit a chemo preventive effect.

Adenosine triphosphate (ATP) is an adenine nucleotide containing three phosphate groups esterified to the sugar moiety. Adenosine triphosphate is the energy source in living cells. In physiological conditions, the average concentration varies from 3150 mM in mammalian cells to 1500–1900 mM in human blood cells. Extracellular adenosine and adenosine triphosphate (ATP) are involved in biological processes including neurotransmission, muscle contraction, cardiac function, platelet function, vasodilatation, signal transduction and secretion in a variety of cell types. A large family of membrane-bound receptors mediates cell signalling by ATP and adenosine. These purinergic receptors ultimately determine the variety of effects induced by extracellular ATP and adenosine. ATP and adenosine have strong negative chronotropic and dromotropic effects on the mammalian heart. The sensitivity of the sinus node and the atrioventricular node to ATP and adenosine manifests pronounced variability among species. For more than three decades, ATP has been used routinely in Europe in the acute therapy of paroxysmal supraventricular tachycardia. ATPace™, an injectable formulation of adenosine 5′-triphosphate (ATP), was developed by Cordex Pharma, Inc. (Cordex) as a diagnostic and therapeutic drug for the management of cardiac bradyarrhythmias. Extracellular ATP exerts multiple effects in various cell types by activating cell-surface receptors known as P2 receptors. In the heart, ATP suppresses the automaticity of cardiac pacemakers and atrioventricular (AV) nodal conduction via adenosine, the product of its degradation by ecto-enzymes, as well as by triggering a cardio-cardiac vagal reflex. ATP, given as a rapid intravenous bolus injection, has been used since the late 1940s as a highly effective and safe therapeutic agent for the acute termination of reentrant paroxysmal supraventricular tachycardia (PSVT) involving the AV node. In addition, preliminary studies have shown that ATP can also be used as a diagnostic agent for the identification of several cardiac disorders including sinus node dysfunction (sick sinus syndrome), dual AV nodal pathways, long QT syndrome, and bradycardic syncope. The US Food and Drug Administration has approved Cordex formulation for ATP as an Investigational New Drug and two pathways for its marketing approval; one therapeutic, i.e., acute termination of paroxysmal PSVT, and the other diagnostic, i.e., the identification of patients with bradycardic syncope who can benefit from pacemaker therapy. However later ATPace development for the treatment of bradycardia and paroxysmal supraventricular tachycardia was discontinued.

Adenosine triphosphate (ATP) is an adenine nucleotide containing three phosphate groups esterified to the sugar moiety. Adenosine triphosphate is the energy source in living cells. In physiological conditions, the average concentration varies from 3150 mM in mammalian cells to 1500–1900 mM in human blood cells. Extracellular adenosine and adenosine triphosphate (ATP) are involved in biological processes including neurotransmission, muscle contraction, cardiac function, platelet function, vasodilatation, signal transduction and secretion in a variety of cell types. A large family of membrane-bound receptors mediates cell signalling by ATP and adenosine. These purinergic receptors ultimately determine the variety of effects induced by extracellular ATP and adenosine. ATP and adenosine have strong negative chronotropic and dromotropic effects on the mammalian heart. The sensitivity of the sinus node and the atrioventricular node to ATP and adenosine manifests pronounced variability among species. For more than three decades, ATP has been used routinely in Europe in the acute therapy of paroxysmal supraventricular tachycardia. ATPace™, an injectable formulation of adenosine 5′-triphosphate (ATP), was developed by Cordex Pharma, Inc. (Cordex) as a diagnostic and therapeutic drug for the management of cardiac bradyarrhythmias. Extracellular ATP exerts multiple effects in various cell types by activating cell-surface receptors known as P2 receptors. In the heart, ATP suppresses the automaticity of cardiac pacemakers and atrioventricular (AV) nodal conduction via adenosine, the product of its degradation by ecto-enzymes, as well as by triggering a cardio-cardiac vagal reflex. ATP, given as a rapid intravenous bolus injection, has been used since the late 1940s as a highly effective and safe therapeutic agent for the acute termination of reentrant paroxysmal supraventricular tachycardia (PSVT) involving the AV node. In addition, preliminary studies have shown that ATP can also be used as a diagnostic agent for the identification of several cardiac disorders including sinus node dysfunction (sick sinus syndrome), dual AV nodal pathways, long QT syndrome, and bradycardic syncope. The US Food and Drug Administration has approved Cordex formulation for ATP as an Investigational New Drug and two pathways for its marketing approval; one therapeutic, i.e., acute termination of paroxysmal PSVT, and the other diagnostic, i.e., the identification of patients with bradycardic syncope who can benefit from pacemaker therapy. However later ATPace development for the treatment of bradycardia and paroxysmal supraventricular tachycardia was discontinued.

Adenosine triphosphate (ATP) is an adenine nucleotide containing three phosphate groups esterified to the sugar moiety. Adenosine triphosphate is the energy source in living cells. In physiological conditions, the average concentration varies from 3150 mM in mammalian cells to 1500–1900 mM in human blood cells. Extracellular adenosine and adenosine triphosphate (ATP) are involved in biological processes including neurotransmission, muscle contraction, cardiac function, platelet function, vasodilatation, signal transduction and secretion in a variety of cell types. A large family of membrane-bound receptors mediates cell signalling by ATP and adenosine. These purinergic receptors ultimately determine the variety of effects induced by extracellular ATP and adenosine. ATP and adenosine have strong negative chronotropic and dromotropic effects on the mammalian heart. The sensitivity of the sinus node and the atrioventricular node to ATP and adenosine manifests pronounced variability among species. For more than three decades, ATP has been used routinely in Europe in the acute therapy of paroxysmal supraventricular tachycardia. ATPace™, an injectable formulation of adenosine 5′-triphosphate (ATP), was developed by Cordex Pharma, Inc. (Cordex) as a diagnostic and therapeutic drug for the management of cardiac bradyarrhythmias. Extracellular ATP exerts multiple effects in various cell types by activating cell-surface receptors known as P2 receptors. In the heart, ATP suppresses the automaticity of cardiac pacemakers and atrioventricular (AV) nodal conduction via adenosine, the product of its degradation by ecto-enzymes, as well as by triggering a cardio-cardiac vagal reflex. ATP, given as a rapid intravenous bolus injection, has been used since the late 1940s as a highly effective and safe therapeutic agent for the acute termination of reentrant paroxysmal supraventricular tachycardia (PSVT) involving the AV node. In addition, preliminary studies have shown that ATP can also be used as a diagnostic agent for the identification of several cardiac disorders including sinus node dysfunction (sick sinus syndrome), dual AV nodal pathways, long QT syndrome, and bradycardic syncope. The US Food and Drug Administration has approved Cordex formulation for ATP as an Investigational New Drug and two pathways for its marketing approval; one therapeutic, i.e., acute termination of paroxysmal PSVT, and the other diagnostic, i.e., the identification of patients with bradycardic syncope who can benefit from pacemaker therapy. However later ATPace development for the treatment of bradycardia and paroxysmal supraventricular tachycardia was discontinued.

Imidocarb is a carbanilide derivative with antiprotozoal activity. It is usually administered as the dipropionate salt. Imidocarb is a drug sold under the brand name Imizol and is used to treat canine ehrlichiosis. wo mechanisms of action have been proposed: As the effect of imidocarb on Trypanosoma brucei is antagonized by excess polyamines, it is has been suggested that imidocarb interferes with their production and/or use. Imidocarb blocks the entry of inositol into erythrocytes containing Babesia, resulting in starvation of the parasite. It is generally accepted in that imidocarb has anticholinesterase activity.

Imidocarb is a carbanilide derivative with antiprotozoal activity. It is usually administered as the dipropionate salt. Imidocarb is a drug sold under the brand name Imizol and is used to treat canine ehrlichiosis. wo mechanisms of action have been proposed: As the effect of imidocarb on Trypanosoma brucei is antagonized by excess polyamines, it is has been suggested that imidocarb interferes with their production and/or use. Imidocarb blocks the entry of inositol into erythrocytes containing Babesia, resulting in starvation of the parasite. It is generally accepted in that imidocarb has anticholinesterase activity.

Fenethylline (generic name Captagon) is a codrug of amphetamine and theophylline. In the fenetylline molecule, theophylline is covalently linked with amphetamine via an alkyl chain. It was formerly used to treat conditions such as ADHD, narcolepsy, and depression, but its use has been banned because of the potential for abuse. Amphetamine, an agonist for trace amine-associated receptor 1 (TAAR1) with enhancing dopamine signaling (an increase of irritability, aggression, etc.), is the main cause of Captagon addiction. Theophylline, an antagonist that blocks adenosine receptors (e.g. A2aR) in the brain responsible for restlessness and painlessness, may attenuate the behavioral sensitization caused by amphetamine. Fenethylline is included in a list of compounds to be considered by a World Health Organization (WHO) Expert Committee in April 1985 for possible international scheduling under the Convention on Psychotropic Substances, 1971. Fenethylline re-emerged because of its widespread abuse by Middle Eastern young adults. Terrorist groups such as the Islamic State to enhance what they consider desirable characteristics - aggressiveness, alertness, and fearlessness - in their recruits, promote it.